MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(Marketwire - June 24, 2008) - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today reported that patients in the DiabeCell® phase I/IIa diabetes clinical trial had porcine insulin in their blood samples providing additional scientific confirmation that implants of DiabeCell® actively produce insulin and directly contribute to clinical benefit.
